Multiple Sclerosis (MS) is an autoimmune
disease in which, many people think, the body's immune system attacks the myelin sheath around nerve axons.
There is some evidence that this attack is triggered, at least in some cases,
by a viral or bacterial infection.
If it indeed turns out that MS is
fundamentally caused by a central nervous system (CNS) infection, it becomes an excellent
candidate for IPT, which has reportedly been used with such effectiveness against
syphilis, herpes, and HIV infections of the CNS. One could hypothesize, therefore,
that IPT, with its apparent ability to transport antiviral and antibiotic drugs into even
the least accessible compartments of the CNS, might be an ideal treatment to try for
eliminating such hidden infections in MS patients. Perhaps IPT could also help bring
the immune system back into balance, as it apparently does in arthritis and other
immune-related diseases. And, by analogy to the apparent nerve regeneration by IPT
in polio and stroke patients, when used in combination with the right drugs and/or nutrients,
IPT may also help rebuild the myelin on damaged nerves in MS patients.
IGF-1, with which insulin cross-reacts, is a known potent stimulator of
myelination (Endocrinology 140(7):3063-3072).
Enough theory. What about practice?
The late Jean-Claude Paquette MD, in his book Medicine
of Hope, claims to have treated one MS
patient using IPT, the first such case in history. Before
treatment, the 43-year-old woman complained of fatigue, could only walk 100
meters, and spent most of the day in bed. After the first IPT treatment,
she felt more energy, could go shopping by herself, and did not have to go to
bed when she got back. After the third treatment, she spent the holidays
without fatigue, even with many house guests and late nights. And after
the fourth treatment she was planning to go cross-country skiing. He lost
touch with her after that, so we do not know the long-term outcome. And we
do not yet know what medications he used for her IPT treatments, although the
details are probably still among his papers.
Isn't this enough of a clue for someone to try IPT for some more MS
patients? As Dr. Paquette said it, "If we never test this therapy in
diseases known as irreversible, who will be able to appreciate it fully?"